Trial Profile
Relevance of Maintenance Therapy Using Lenalidomide (Revimid) After Autologous Stem Cell Transplantation Patients Under the Age Of 65. (Open, Randomised, Multi-centric Trial Versus Placebo).
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 29 Apr 2019
Price :
$35
*
At a glance
- Drugs Lenalidomide (Primary)
- Indications Multiple myeloma
- Focus Registrational; Therapeutic Use
- 25 Apr 2019 Status changed from active, no longer recruiting to completed.
- 03 Jan 2018 Planned End Date changed from 1 Sep 2017 to 1 Sep 2020.
- 24 Feb 2017 According to a Celgene Corporation media release,the European Commission approved REVLIMID as Monotherapy for the Maintenance Treatment of Patients with Newly Diagnosed Multiple Myeloma after Autologous Stem Cell Transplantation.